Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler

P. W. Jones, E. Ståhl, K. Svensson (London, United Kingdom; Lund, Sweden)

Source: Annual Congress 2002 - COPD - Quality of life and symptoms
Session: COPD - Quality of life and symptoms
Session type: Thematic Poster Session
Number: 1613
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. W. Jones, E. Ståhl, K. Svensson (London, United Kingdom; Lund, Sweden). Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. Eur Respir J 2002; 20: Suppl. 38, 1613

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Budesonide/formoterol in a single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 397s
Year: 2002

Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs
Source: Eur Respir J 2003; 22: Suppl. 45, 50s
Year: 2003

Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013

Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013


Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 242s
Year: 2002

Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013

Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 21s
Year: 2001

Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1-year study
Source: Eur Respir J 2002; 20: Suppl. 38, 242s
Year: 2002

Budesonide/formoterol in a single inhaler rapidly improves lung function in adult patients with mild or moderate asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 387s
Year: 2002

Evaluation of adherence of patients with asthma to treatment by single combination inhaler
Source: Eur Respir J 2006; 28: Suppl. 50, 499s
Year: 2006

Beclometasone diproprionate/formoterol in a single inhaler improves lung function and clinically meaningful outcomes in moderate to severe asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006

A new budesonide/formoterol inhalation therapy in patients with asthma, COPD and ACOS
Source: International Congress 2017 – Bronchial asthma management
Year: 2017

Cost-effectiveness of fluticasone/salmeterol inhaler in treatment of moderate and severe bronchial asthma
Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma
Year: 2008


Efficacy of a combination therapy with single inhaler budesonide/formoterol in the treatment of acute exacerbations of COPD (AECOPD)
Source: Eur Respir J 2004; 24: Suppl. 48, 252s
Year: 2004

QVA149 showed significant improvements in lung function and health status and was well tolerated versus glycopyrronium and tiotropium in patients with severe COPD: The SPARK study
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014



Improved asthma control with budesonide/formoterol via a single inhaler, compared with budesonide alone, in moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 48s
Year: 2001

QVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: The ARISE study
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013

Comparison of efficacy and safety of Obucort Swinghaler with Pulmicot Turbuhaler in mild to moderate severe asthma patients
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I
Year: 2010

Economic evaluation of beclomethasone/formoterol versus budesonide/formoterol in the treatment of patient with moderate-severe asthma in Spain
Source: Annual Congress 2008 - Impact of patient education on cost-effectiveness of treatment
Year: 2008


Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009